Skip to content

Study · Observational study · n = 334 · 2020

7 results

Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.

Wu M, Ji JJ, Zhong L, Shao ZY, Xie QF, Liu ZY, Wang CL, Su L, Feng YW, Liu ZF, Yao YM

International immunopharmacology6 Aug 2020Cited by 32 (Europe PMC)

PMID32795897 (opens in a new tab)PMCIDPMC7409727 (opens in a new tab)DOI10.1016/j.intimp.2020.106873 (opens in a new tab)PepBankPUB-32795897
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with COVID-19, 28-day mortality differed between thymosin α1-treated and untreated groups in the adjusted model.

    In plain wordsIn adults with COVID-19, 28-day death rates differed between patients treated with thymosin α1 and those not treated.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reported28-day mortality, overall cohort
    Study

    n = 334

    Comparator
    Non-thymosin α1-treated patients
    Analysis
    Primary
    Outcome group
    Mortality · Infection
    Studied dose
    1.6 mg qd or q12 h · >5 daysAs given in this study (human).

    Source sentences

    Summary
    There was a significant difference in the 28-day mortality between the thymosin α1 and non-thymosin α1-treated groups in adjusted model (P = 0.016)
    3 context sentences
    Summary · context
    The primary outcomes were the 28-day and 60-day mortality, the secondary outcomes were hospital length of stay and the total duration of the disease.
    Summary · context
    This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec.
    Summary · context
    Thymosin α1 was administrated with 1.6 mg qd or q12 h for >5 days.
  2. 02HumanObservational studyEfficacy outcome

    In adults with COVID-19, 60-day mortality did not differ obviously between thymosin α1-treated and untreated groups.

    In plain wordsIn adults with COVID-19, 60-day death rates were not clearly different with or without thymosin α1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant change60-day mortality, overall cohort
    Study

    n = 334

    Comparator
    Non-thymosin α1-treated patients
    Analysis
    Primary
    Outcome group
    Mortality · Infection
    Studied dose
    1.6 mg qd or q12 h · >5 daysAs given in this study (human).

    Source sentences

    Summary
    without obvious differences in the 60-day mortality and survival time in the overall cohort (P > 0.05).
    2 context sentences
    Summary · context
    This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec.
    Summary · context
    Thymosin α1 was administrated with 1.6 mg qd or q12 h for >5 days.
  3. 03HumanObservational studyEfficacy outcome

    In adults with critical type COVID-19, thymosin α1 therapy significantly reduced 28-day mortality.

    In plain wordsIn adults with critical COVID-19, thymosin α1 lowered the chance of death within 28 days compared with no thymosin α1.

    Peptide
    Thymosin alpha-1
    Outcome
    Decrease28-day mortality, critical type patients
    Study

    n: not reported in source

    Comparator
    Non-thymosin α1-treated patients
    Analysis
    Primary
    Outcome group
    Mortality · Infection
    Studied dose
    1.6 mg qd or q12 h · >5 daysAs given in this study (human).

    Measurements

    Hazard ratio
    0.11 ratio
    28-day mortality, critical type

    Source sentences

    Summary
    thymosin α1 therapy significantly reduced 28-day mortality (Hazards Ratios HR, 0.11, 95% confidence interval CI 0.02-0.63, P=0.013)
    3 context sentences
    Summary · context
    in the critical type patients
    Summary · context
    This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec.
    Summary · context
    Thymosin α1 was administrated with 1.6 mg qd or q12 h for >5 days.
  4. 04HumanObservational studyEfficacy outcome

    In adults with critical type COVID-19, thymosin α1 therapy prolonged the hospital length of stay.

    In plain wordsIn adults with critical COVID-19, thymosin α1 was linked to a longer hospital stay.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHospital length of stay in critical type patients
    Study

    n: not reported in source

    Comparator
    Non-thymosin α1-treated patients
    Analysis
    Secondary
    Outcome group
    Intensive care and hospital outcomes · Infection
    Studied dose
    1.6 mg qd or q12 h · >5 daysAs given in this study (human).

    Source sentences

    Summary
    prolonged the hospital length of stay (P = 0.024)
    2 context sentences
    Summary · context
    This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec.
    Summary · context
    Thymosin α1 was administrated with 1.6 mg qd or q12 h for >5 days.
  5. 05HumanObservational studyEfficacy outcome

    In adults with critical type COVID-19, thymosin α1 therapy prolonged the total duration of the disease.

    In plain wordsIn adults with critical COVID-19, thymosin α1 was linked to a longer total illness.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTotal duration of disease in critical type patients
    Study

    n: not reported in source

    Comparator
    Non-thymosin α1-treated patients
    Analysis
    Secondary
    Outcome group
    Intensive care and hospital outcomes · Infection
    Studied dose
    1.6 mg qd or q12 h · >5 daysAs given in this study (human).

    Source sentences

    Summary
    as well as the total duration of the disease (P=0.001)
    2 context sentences
    Summary · context
    This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec.
    Summary · context
    Thymosin α1 was administrated with 1.6 mg qd or q12 h for >5 days.
  6. 06HumanObservational studyEfficacy outcome

    In adults with COVID-19, survival time did not differ obviously between thymosin α1-treated and untreated groups.

    In plain wordsIn adults with COVID-19, survival time was not clearly different with or without thymosin α1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSurvival time, overall cohort
    Study

    n = 334

    Comparator
    Non-thymosin α1-treated patients
    Outcome group
    Mortality · Infection
    Studied dose
    1.6 mg qd or q12 h · >5 daysAs given in this study (human).

    Source sentences

    Summary
    without obvious differences in the 60-day mortality and survival time in the overall cohort (P > 0.05).
    2 context sentences
    Summary · context
    This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec.
    Summary · context
    Thymosin α1 was administrated with 1.6 mg qd or q12 h for >5 days.
  7. 07HumanObservational studyEfficacy outcome

    In adults with critical type COVID-19, thymosin α1 therapy was linked to improved PaO2/FiO2.

    In plain wordsIn adults with critical COVID-19, thymosin α1 was linked to better blood oxygen measures.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePaO2/FiO2 in critical type patients
    Study

    n: not reported in source

    Comparator
    Non-thymosin α1-treated patients
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    1.6 mg qd or q12 h · >5 daysAs given in this study (human).

    Source sentences

    Summary
    via improvement of Pa02/FiO2 (P = 0.036)
    2 context sentences
    Summary · context
    This multicenter retrospective cohort study was performed in 8 government-designated treatment centers for COVID-19 patients in China from Dec.
    Summary · context
    Thymosin α1 was administrated with 1.6 mg qd or q12 h for >5 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.